bulevirtide (Pending FDA Approval)

Brand and Other Names:Hepcludex
  • Print

Dosing & Uses

Hepatitis D Infection

Pending FDA approval for treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease

Next:

Pharmacology

Mechanism of Action

First-in-class sodium taurocholate cotransporting polypeptide (NTCP) blocker; NTCP serves to transport bile acids to the liver from the portal circulation as an important component of enterohepatic circulation

Hepatitis D virus (HDV) replicates independently within liver cells, but requires hepatitis B surface antigen to propagate; hepatitis B and D viruses enter hepatocytes through binding of NTCP to hepatitis B virus preS1 surface protein domain

Bulevirtide binds and subsequently inactivates HBV and HDV receptors on hepatocytes; it also blocks NTCP binding site, subsequently blocking HBV and HDV viral entry into cells resulting in prevention of viral replication

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.